nafamostat has been researched along with Glaucoma in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuda, Y | 1 |
| Nakahara, T | 1 |
| Ueda, K | 1 |
| Mori, A | 1 |
| Sakamoto, K | 1 |
| Ishii, K | 1 |
1 other study available for nafamostat and Glaucoma
| Article | Year |
|---|---|
Effect of nafamostat on N-methyl-D-aspartate-induced retinal neuronal and capillary degeneration in rats.
Topics: Animals; Basement Membrane; Benzamidines; Capillaries; Diabetic Neuropathies; Excitatory Amino Acid | 2012 |